ArticleOncoimmunology
Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.Journal of neuro-oncology · 2020Trial
- Tumor Microenvironments in Malignant Ovarian Germ Cell Tumors: MHC Class I Loss and T-Cell Exhaustion in Dysgerminoma.Cancer science · 2026Article
- Integrative proteogenomic characterization of Wilms tumor.Nature communications · 2025Article
- Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors.Cytotherapy · 2025Article
- The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors.Frontiers in immunology · 2025Article
- Bisphenol-A in Drinking Water Accelerates Mammary Cancerogenesis and Favors an Immunosuppressive Tumor Microenvironment in BALB-International journal of molecular sciences · 2024Article
- Subgrouping testicular germ cell tumors based on immunotherapy and chemotherapy associated lncRNAs.Heliyon · 2024Article
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
- Review
- Immune-related mechanisms and immunotherapy in extragonadal germ cell tumors.Frontiers in immunology · 2023Review
- Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors.Frontiers in immunology · 2023Review
- Case Report: From epilepsy and uterus didelphys to Turner syndrome-associated dysgerminoma.Frontiers in genetics · 2023Article
- Profiling the 3D interaction between germ cell tumors and microenvironmental cells at the transcriptome and secretome level.Molecular oncology · 2022Article
- Immunotherapies for Pediatric Solid Tumors: A Targeted Update.Paediatric drugs · 2022Article
- Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes.Cells · 2021Review
- Article
- Rare Diseases of the Oral Cavity, Neck, and Pharynx.Laryngo- rhino- otologie · 2021Review
- Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.